Elephas Biosciences Corporation

Amgen Inc.

Sean Caenepeel

Jonathan Daniel Oliner

Paul G Hughes

Tomasz Zal

Laura Catherine Funk Hrycyniak

Neil Anthony

John Rafter

Anne Y Saiki

Jude Robert Canon

Angela Coxon

Scott Johnson

Robert Loberg

TS Ramasubramanian

Zhiqiang Du

Michael Korrer

Pichet Adstamongkonkul

Gataree Ngarmchamnanrith

Richard J Rickles

Beate Sable

Gift Ngarmchamnanrith

Paul Hughes

Provided herein are systems and methods for measuring cellular activity within a biological sample comprising living cells over an extended time period. In particular, provided herein are techniques for measuring changes in cellular activity within a tissue sample comprising living cells (e.g., a tissue section comprising living cells) during and/or after exposure to a first stimulus (e.g., a control stimulus) at a first time point and during and/or after exposure to a second stimulus (e.g., a non-control stimulus) (e.g., a pharmaceutical stimulus) at a second time point after the first time point.

Systems and methods for measuring changes in cellular activity in live tissue

Provided are ex vivo systems and methods of predicting the response of a drug or other agent on a tissue. In some embodiments, the systems and methods comprise cutting a tissue into tissue fragments, adding a drug or other agent to the tissue fragments based on an estimated tumor content, and performing an ex vivo measurement on the tissue fragments.

Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue

The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

The present invention relates to methods of therapeutic treatment of cancer using selective tyrosine kinase inhibitors and cancer biomarkers, such as MET amplification and high Met expression for patient selection.

Biomarkers and use of MET inhibitor for treatment of cancer

Growing community of inventors

Thousand Oaks, CA, United States of America

Sean Caenepeel